SMT202200013T1 - Derivati di xantina sostituiti - Google Patents
Derivati di xantina sostituitiInfo
- Publication number
- SMT202200013T1 SMT202200013T1 SM20220013T SMT202200013T SMT202200013T1 SM T202200013 T1 SMT202200013 T1 SM T202200013T1 SM 20220013 T SM20220013 T SM 20220013T SM T202200013 T SMT202200013 T SM T202200013T SM T202200013 T1 SMT202200013 T1 SM T202200013T1
- Authority
- SM
- San Marino
- Prior art keywords
- xanthine derivatives
- substituted xanthine
- substituted
- derivatives
- xanthine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17180721 | 2017-07-11 | ||
| EP18735588.8A EP3652176B1 (en) | 2017-07-11 | 2018-07-06 | Substituted xanthine derivatives |
| PCT/EP2018/068366 WO2019011802A1 (en) | 2017-07-11 | 2018-07-06 | NEW SUBSTITUTED XANTHINE DERIVATIVES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT202200013T1 true SMT202200013T1 (it) | 2022-03-21 |
Family
ID=59325162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20220013T SMT202200013T1 (it) | 2017-07-11 | 2018-07-06 | Derivati di xantina sostituiti |
Country Status (32)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3093084A1 (en) * | 2018-03-05 | 2019-09-12 | Goldfinch Bio, Inc. | Imidazodiazepinediones and methods of use thereof |
| JP7408662B2 (ja) * | 2018-12-12 | 2024-01-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換キサンタン誘導体 |
| JP7502299B2 (ja) * | 2018-12-12 | 2024-06-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換キサンチン誘導体 |
| JP2022551580A (ja) * | 2019-10-04 | 2022-12-12 | ゴールドフィンチ バイオ，インク． | 巣状分節性糸球体硬化症および糖尿病性腎症のバイオマーカーに基づく処置 |
| CN118373832B (zh) * | 2023-01-20 | 2025-01-28 | 深圳晶蛋生物医药科技有限公司 | 大环类化合物、其药物组合物及其应用 |
| KR20250141831A (ko) | 2023-02-08 | 2025-09-29 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | 잔틴계 화합물 및 이의 용도 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03007349A (es) * | 2001-02-24 | 2003-12-04 | Boehringer Ingelheim Pharma | Derivados de xantina, su preparacion y su empleo como medicamentos. |
| US6869947B2 (en) * | 2001-07-03 | 2005-03-22 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
| MX2009000508A (es) * | 2006-07-14 | 2009-01-27 | Pfizer Prod Inc | Sal tartrato de (7s)-7-[(5-fluoro-2-metil-bencil)oxi]-2-[(2r)-2-me tilpiperazin-1-il]-6,7-dihidro-5h-ciclopenta[b]piridina. |
| EP2970303B3 (en) * | 2013-03-15 | 2018-08-01 | Hydra Biosciences, Inc. | Substituted xanthines and methods of use thereof |
| TWI676626B (zh) * | 2014-04-23 | 2019-11-11 | 美商美國禮來大藥廠 | 抑制瞬時受體電位ａ１離子通道 |
| WO2016023830A1 (en) | 2014-08-11 | 2016-02-18 | Hydra Biosciences, Inc. | Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives |
| EP3180342B1 (en) | 2014-08-11 | 2019-06-26 | Hydra Biosciences, Inc. | Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives |
| EP3194367B1 (en) | 2014-09-17 | 2021-08-18 | Boehringer Ingelheim International GmbH | Tetrahydroisoquinoline derivatives and pharmaceutical compositions useful for the treatment of obesity and diabetes |
-
2018
- 2018-07-06 CN CN201880045961.0A patent/CN110997675B/zh active Active
- 2018-07-06 UA UAA202000735A patent/UA124793C2/uk unknown
- 2018-07-06 CA CA3066922A patent/CA3066922A1/en active Pending
- 2018-07-06 KR KR1020207000260A patent/KR102714554B1/ko active Active
- 2018-07-06 SM SM20220013T patent/SMT202200013T1/it unknown
- 2018-07-06 AU AU2018299824A patent/AU2018299824B2/en active Active
- 2018-07-06 ES ES18735588T patent/ES2903268T3/es active Active
- 2018-07-06 DK DK18735588.8T patent/DK3652176T3/da active
- 2018-07-06 EA EA202090270A patent/EA039526B1/ru unknown
- 2018-07-06 LT LTEPPCT/EP2018/068366T patent/LT3652176T/lt unknown
- 2018-07-06 PL PL18735588T patent/PL3652176T3/pl unknown
- 2018-07-06 HR HRP20220029TT patent/HRP20220029T1/hr unknown
- 2018-07-06 PE PE2019002691A patent/PE20200861A1/es unknown
- 2018-07-06 SG SG11201912168TA patent/SG11201912168TA/en unknown
- 2018-07-06 RS RS20211577A patent/RS62826B1/sr unknown
- 2018-07-06 MX MX2020000402A patent/MX394089B/es unknown
- 2018-07-06 JP JP2020523041A patent/JP7114702B2/ja active Active
- 2018-07-06 MY MYPI2019007689A patent/MY200797A/en unknown
- 2018-07-06 HU HUE18735588A patent/HUE057600T2/hu unknown
- 2018-07-06 WO PCT/EP2018/068366 patent/WO2019011802A1/en not_active Ceased
- 2018-07-06 IL IL271799A patent/IL271799B/en unknown
- 2018-07-06 EP EP18735588.8A patent/EP3652176B1/en active Active
- 2018-07-06 PT PT187355888T patent/PT3652176T/pt unknown
- 2018-07-06 SI SI201830519T patent/SI3652176T1/sl unknown
- 2018-07-10 US US16/031,399 patent/US10329292B2/en active Active
- 2018-07-10 TW TW107123858A patent/TWI801398B/zh active
- 2018-07-11 AR ARP180101931 patent/AR112448A1/es unknown
-
2019
- 2019-12-18 SA SA519410851A patent/SA519410851B1/ar unknown
- 2019-12-30 CO CONC2019/0015102A patent/CO2019015102A2/es unknown
-
2020
- 2020-01-08 CL CL2020000056A patent/CL2020000056A1/es unknown
- 2020-01-10 PH PH12020500079A patent/PH12020500079A1/en unknown
-
2022
- 2022-01-12 CY CY20221100028T patent/CY1125014T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271290A (en) | Dihydro-pyrrolo-pyridine derivatives | |
| ZA201907397B (en) | Cellulose derivatives | |
| IL271607A (en) | New azaquinoline histories | |
| ZA201800826B (en) | Substituted oxopyridine derivatives | |
| IL253381A0 (en) | History of h9-pyrrolo-dipyridine | |
| PL3359543T3 (pl) | Pochodne kukurbiturylu | |
| IL283990A (en) | Modified oxopyridine derivatives | |
| IL271799A (en) | New transmuted xanthine histories | |
| SG11202012594RA (en) | Spirochromane derivatives | |
| ZA201801718B (en) | Hydroxyalkyl thiadiazole derivatives | |
| IL271665A (en) | benzazapine derivatives | |
| LT3796975T (lt) | Sulfonilaminobenzamido dariniai | |
| IL251005B (en) | Pyrido-oxazinone derivatives | |
| HUE064908T2 (hu) | Szubsztituált xantinszármazékok | |
| PL3770162T3 (pl) | Pochodne dihydrochromenu | |
| GB201416351D0 (en) | Heterocyclic derivatives | |
| IL265182A (en) | proinsulin derivatives | |
| IL255829B (en) | Xanthine derivative | |
| GB201806948D0 (en) | Derivatives | |
| PT3319956T (pt) | Derivados de oxopiridina substituída |